This Month in JNM

Late effects of radioablation: Reiners and colleagues review recent literature on the risk of secondary cancers after radiation treatment and preview an article in this issue of JNM on potential sequelae to radioiodine ablation in children near Chernobyl.
Page 1563

Optimal patient selection for CRT: Ypenburg and colleagues assess whether the extent of myocardial viability on ¹⁸F-FDG SPECT at intervention can accurately forecast the success of cardiac resynchronization therapy in patients with heart failure.
Page 1565

Enhanced imaging of granulomas: Nishiyama and colleagues compare tracer uptake on ¹⁸F-FDG PET and ⁶⁷Ga whole-body planar and thoracic imaging in the evaluation of pulmonary and extrapulmonary involvement in patients with sarcoidosis.
Page 1571

Strategic approach to heel pain: Frater and colleagues devise a set of scintigraphic criteria based on blood-pool abnormalities to predict the success of steroid injection therapies in patients with plantar fasciitis.
Page 1577

Noninvasive misery perfusion evaluation: Kobayashi and colleagues describe a novel technique for measuring asymmetric increases in oxygen extraction fraction in H₂¹⁵O PET studies in cerebrovascular disease and point to advantages in technical simplicity and decreased patient discomfort.
Page 1581

Reevaluating ¹³¹I doses in the elderly: Tuttle and colleagues look at age-associated differences in maximum tolerated activity in fixed-dose ¹³¹I therapy for metastatic thyroid cancer.
Page 1587

PET and bone marrow cellularity: Agool and colleagues investigate the feasibility of using ¹⁸F-FLT PET to visualize and quantify proliferative activity in the bone marrow compartment to differentiate among various hematologic disorders.
Page 1592

Identifying somatostatin receptor subtypes: van Essen and colleagues describe the effects of ¹⁷⁷Lu-octreotate therapy in patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas, and melanomas.
Page 1599

Brain PET and operable NSCLC: Posther and colleagues ask whether ¹⁸F-FDG PET provides useful information in patients whose suspected or proven non–small cell lung cancer is considered resectable on the basis of conventional imaging approaches.
Page 1607

Kinetics of ¹⁸F-FLT brain imaging: Muzi and colleagues investigate compartmental modeling of tracer transport and retention in ¹⁸F-FLT studies to assess cellular proliferation in patients with gliomas.
Page 1612

PET and celiac disease progression: Hadithi and colleagues compare ¹⁸F-FDG PET and CT in the detection of enteropathy-associated T-cell lymphoma in patients with refractory celiac disease.
Page 1622

PET/CT vs. CT in thymic tumors: Sung and colleagues assess the utility of ¹⁸F-FDG PET/CT in distinguishing subgroups of thymic epithelial tumors and for staging extent of disease.
Page 1628

PET/CT in SNS imaging: Franzius and colleagues evaluate the feasibility of whole-body ¹¹C-HED PET/low-dose CT for examination of tumors of the sympathetic nervous system and compare the results with those from ¹²³I-MIBG scintigraphy and SPECT/CT.
Page 1635

Effective PET/CT dose reduction: Rodríguez-Vigil and colleagues compare contrast-enhanced full-dose PET/CT and unenhanced low-dose ¹⁸F-FDG PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma.
Page 1643

Novel tracer for prostate imaging: Peng and colleagues investigate the use of ⁶⁴CuCl₂ as a probe in PET localization of human prostate cancer xenografts in mice and discuss the implications for clinical use in locally recurrent tumors.
Page 1649

Radiologic threat preparedness: Barnett and colleagues provide an educational overview of radiologic and nuclear terrorism as public health threats and discuss appropriate preparedness and response perspectives for nuclear medicine professionals.
Page 1653

Optimizing clinical SPECT: Xiao and colleagues compare the performances of Monte Carlo–based and window-based scatter correction in ^99mTc SPECT cardiac imaging.
Page 1662

Molecular targeting of mRNA: Watanabe and colleagues investigate the therapeutic effect of Auger electrons emitted by ¹¹¹In-labeled phosphorothioate antisense oligonucleotides on human neuroblastoma cells.
Page 1670

ImmunoPET investigations: McBride and colleagues continue their work with bispecific antibody pretargeting for tumor imaging, here reporting on a radioiodination procedure to assess PET imaging with ¹²⁴I.
Page 1678

Tracing dependence: Horti and colleagues evaluate an ¹¹C-labeled analog of a cerebral cannabinoid receptor antagonist as a potential radioligand for PET imaging of addiction and related neuropsychiatric disorders.
Page 1689

Novel serotonin agent: Saigal and colleagues report on the radiosynthesis and in vitro and in vivo binding characteristics of ¹⁸F-mefway, a more stable serotonin 5-HT_1A agent for use in PET imaging in disorders of the central nervous system.
Page 1697

^99mTc-labeled fibronectin antibodies: Berndorff and colleagues detail the synthesis and ^99mTc labeling of compounds to target the angiogenesis-associated extracellular matrix protein ED-B fibronectin for scintigraphic molecular imaging of solid tumors.
Page 1707

DNA synthesis imaging: Toyohara and colleagues describe the production of a novel thymidine analog for simplified ¹¹C-PET imaging of DNA synthesis in tumor cell proliferation.
Page 1717

Long-term follow-up recommended: Travis and Stabin review treatment data from children in the Chernobyl area who underwent radioiodine ablation and estimate the increased risk of cancers––including breast cancer––in this population.
Page 1723

ON THE COVER

Because serotonin 5-HT_1A receptors have been implicated in disorders of the central nervous system, efforts are under way to develop fluorinated PET radiotracers that are stable to metabolism, easily synthesized, and highly selective for 5-HT_1A receptors. ¹⁸F-Mefway has shown value as such a radiotracer and is, in addition, sensitive to being displaced by serotonin, suggesting potential as a PET agent for measuring changes in serotonin concentration in the living brain.

SEE PAGE 1703